Literature DB >> 8776353

The cost of atopic eczema.

R M Herd1, M J Tidman, R J Prescott, J A Hunter.   

Abstract

Atopic eczema affects 2.3% of the U.K. population. We have carried out a community study in a semi-rural area to assess its economic impact. One hundred and fifty-five patients with atopic eczema were identified and expenditure was assessed over a 2-month period. The mean personal cost to the patient was pounds 25.90, while the mean cost to the health service was pounds 16.20. There were 58 lost working days and 17 lost school days. A cohort of 10 severely affected patients attending the Royal Infirmary of Edinburgh were studied; each patient spent, on average, pounds 325 in 2 months, and lead to a mean health service expenditure per patient of pounds 415, in 2 months. If these results were extrapolated to the U.K. population, the annual personal cost to patients with atopic eczema would be pounds 297m, the cost to the health service would be pounds 125m, and the annual cost to society of lost working days would be pounds 43m, making the total expenditure on atopic eczema pounds 465m.

Entities:  

Mesh:

Year:  1996        PMID: 8776353

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  19 in total

1.  The effect of TJ-15 plus TJ-17 on atopic dermatitis: a pilot study based on the principle of pattern identification.

Authors:  In-Hwa Choi; Sehyun Kim; YoungChul Kim; Younghee Yun
Journal:  J Altern Complement Med       Date:  2012-06       Impact factor: 2.579

Review 2.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 3.  The economics of topical immunomodulators for the treatment of atopic dermatitis.

Authors:  William Abramovits; Mark Boguniewicz; Amy S Paller; Diane L Whitaker-Worth; Mary M Prendergast; Michael Tokar; Kuo B Tong
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Prednicarbate versus fluocortin for inflammatory dermatoses. A cost-effectiveness study.

Authors:  A de Tiedra; J Mercadal; R Lozano
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

5.  Successful treatment of a patient with severe atopic dermatitis and severe asthma by centrifugal therapeutic plasma exchange.

Authors:  Louise Fuller; Benit Maru; Neil Isserlis; Rino Cerio
Journal:  BMJ Case Rep       Date:  2015-05-12

6.  Metabolism and activation of polychlorinated biphenyls (PCBs).

Authors:  L W Robertson; P Espandiari; H J Lehmler; D Pereg; A Srinivasan; N Tampal; T Twaroski; G Ludewig; H P Glauert; J Arif; R Gupta
Journal:  Cent Eur J Public Health       Date:  2000-07       Impact factor: 1.163

7.  Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema--a long-term analysis from a Swiss perspective.

Authors:  Patricia R Blank; Armin A Blank; Thomas D Szucs
Journal:  BMC Dermatol       Date:  2010-06-25

Review 8.  Cost of illness of atopic dermatitis in children: a societal perspective.

Authors:  Andrew S Kemp
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  The Use of Decision-Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal.

Authors:  Emma McManus; Tracey Sach; Nick Levell
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981

Review 10.  Oral evening primrose oil and borage oil for eczema.

Authors:  Joel T M Bamford; Sujoy Ray; Alfred Musekiwa; Christel van Gool; Rosemary Humphreys; Edzard Ernst
Journal:  Cochrane Database Syst Rev       Date:  2013-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.